At ABCD Antibodies, we have a long-standing connection with the soil amoeba Dictyostelium discoideum. Like many niche model organisms, Dicty suffers from a limited availability of high-quality antibodies. This is an issue that dramatically slows down research on such organisms.
This challenge actually shaped our journey: it pushed us to develop deep expertise in antibody sequencing, recombinant production, customization, and screening using phage display.
What started as a solution for our own research has grown into a broader mission: promoting the adoption of recombinant antibodies across life sciences.
🤝 Today, we’re excited to share 5 new validated antibodies developed in collaboration with labs from Université de Genève:
➡️ ABCD_RB861, RB863, RB865 against dstA
➡️ ABCD_RB874 against dstC
➡️ ABCD_RC012 against aplA
🧪 With nearly 100 dedicated antibodies now available, we’re proud to support the Dicty community with reliable, well-characterized tools.
Image credit: Usman Bashir, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=45043878
